Moreover, the PI3K/AKT/mTOR pathway is frequently hyperactivated in renal cancer, often in conjunction with VHL–HIF signaling, creating a distinctive therapeutic vulnerability. This evidence concerns the gene AKT1 and renal carcinoma.